On February 28, 2022 Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update (Press release, Protagonist, FEB 28, 2022, View Source [SID1234609146]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This past quarter and the year leading up to it has been a transformational period for Protagonist," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "Today, we are closer than ever to fulfilling the potential of three diverse strategies reflected in our robust pipeline: (1) moving rusfertide into a Phase 3 registrational study for a rare disease indication like polycythemia vera, (2) completing enrollment for PN-943 Phase 2 proof-of-concept study in a common and prevalent disease like ulcerative colitis, and (3) enabling our partner, Janssen, to progress PN-235 into a Phase 2b study in plaque psoriasis and potentially other indications in inflammatory bowel diseases in the later part of the year. Each of these three assets and their potential to treat diverse diseases represent a multi-billion-dollar opportunity for Protagonist."
Dr. Patel continued: "In the last quarter and year, we have demonstrated exceptional strength of execution in progressing our assets further in clinical development. For rusfertide in PV, we announced updated Phase 2 data at EHA (Free EHA Whitepaper) and ASH (Free ASH Whitepaper), and recently unveiled the design of our Phase 3 VERIFY study, which is set to initiate this quarter. With great anticipation, we look forward to the topline data readout from the Phase 2 IDEAL study of PN-943 in ulcerative colitis in the second quarter of this year. We’re very pleased that the 240-patient Phase 2b study of PN-235 in plaque psoriasis has initiated, with the first patient dosed recently. Looking ahead, we plan to continue to demonstrate our strength of execution across all current and emerging assets in our pipeline, thereby maximizing the opportunities ahead of us for substantial value creation this year."
Fourth Quarter 2021 Recent Developments and Upcoming Milestones
Rusfertide: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV) and Other Blood Disorders
Most recent data from the ongoing Phase 2 REVIVE study of rusfertide in PV were presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) December 2021 Annual Meeting. Findings from the open label portion of this study continued to demonstrate rusfertide’s ability to markedly reduce the need for therapeutic phlebotomies (TP) in a majority of PV patients, along with additional observed effects including rapid, sustained, and durable hematocrit (HCT) control.
Also at ASH (Free ASH Whitepaper) 2021, the Company presented results from the PACIFIC Phase 2 study of rusfertide for PV patients with high HCT levels. Data demonstrated that post-induction, weekly rusfertide treatment rapidly controlled HCT levels without the need for TP.
Protagonist is preparing to initiate the VERIFY study, a pivotal Phase 3 clinical trial of rusfertide for 250 patients living with PV, in Q1 2022. The design of the upcoming clinical trial was also presented at ASH (Free ASH Whitepaper) in December 2021.
Data from an open-label Phase 2 clinical trial of rusfertide in HH were presented at The Liver Meeting in November 2021, hosted by the American Association for the Study of Liver Diseases. This data demonstrated rusfertide’s ability to reduce phlebotomy rates and other biomarkers associated with the disease in the study population. The Company plans to identify potential target sub-populations and next steps in 1H 2022 to advance the program.
PN-943: Oral, gut-restricted, alpha-4-beta-7 Integrin Antagonist for Ulcerative Colitis (UC)
PN-943 is currently being evaluated in moderate-to-severe UC in the Company’s Phase 2 IDEAL study. The clinical trial has completed its target enrollment of 150 patients, and the Company plans to share topline results from the study, including data from the 12-week induction period, in Q2 2022.
PN-235: Oral IL-23 Receptor Antagonist
A Phase 2b study of PN-235 (JNJ-77242113) in participants with moderate-to-severe plaque psoriasis (FRONTIER 1) initiated in early 2022, sponsored by Janssen Biotech (Janssen). PN-235 is a second-generation oral peptide IL-23 receptor antagonist being developed under the worldwide license and collaboration agreement with Janssen. PN-235 is also expected to advance into Phase 2 clinical studies in inflammatory bowel diseases in 2H 2022. The Company will earn a $25 million milestone in connection with the dosing of a third patient in FRONTIER 1. Protagonist is also eligible for a $10 million milestone in connection with the start of the second indication-based Phase 2 study.
Fourth Quarter 2021 Financial Results
Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2021 were $326.9 million. The Company expects current cash, cash equivalents and marketable securities to be sufficient to fund its planned operating and capital expenditures through 2024. Our cash forecast will be updated following the PN-943 Phase 2 study UC data readout in the second quarter of 2022.
License and Collaboration Revenue: License and collaboration revenue was $8.6 million for the fourth quarter of 2021 compared to $5.7 million for the same period of 2020. The increase was primarily due to an increase in services provided to Janssen under the collaboration agreement during 2021 related to PN-232 and PN-235 as the company nears completion of the services to be performed. License and collaboration revenue for the full year 2021 was $27.4 million compared to $28.6 million for 2020. The full year 2021 collaboration revenue included a cumulative catch-up amount of $8.0 million following the July 2021 amendment of its collaboration agreement for the development of IL23-R assets with Janssen. Revenue for the prior year 2020 included an update to the forecast for remaining services to be completed under the collaboration, which accelerated our overall percentage completion under the accounting performance obligation and accelerated revenue recognition.
Research and Development ("R&D") Expenses: R&D expenses for the fourth quarter and full year 2021 were $38.4 million and $126.0 million respectively, as compared to $19.5 million and $74.5 million, respectively, for the same periods of 2020. The increases in 2021 were primarily due to the additional costs associated with advancing rusfertide and PN-943 through Phase 2 studies and our preparations for future Phase 3 clinical study initiations, as well as expenses related to our Phase 1 studies for our second-generation IL23-R antagonist assets under the Janssen collaboration. R&D expenses also increased due to higher research spending and employee related costs, including stock-based compensation expenses following recent hiring in support of our advancing research and development programs.
General and Administrative ("G&A") Expenses: G&A expenses for the fourth quarter and full year 2021 were $7.3 million and $27.2 million, respectively, as compared to $5.0 million and $18.6 million for the same periods of 2020. The increases were primarily related to professional fees, insurance costs and employee compensation related expenses, including stock-based compensation expenses, supporting the growth in our operations.
Stock-based Compensation ("SBC") Expenses: SBC expenses for the fourth quarter and full year ended December 31, 2021 were $5.0 million and $16.4 million, respectively, as compared to $2.0 million and $7.9 million, respectively, for the same periods of 2020. The increases in 2021 (included in R&D and G&A expenses above) were primarily attributable to awards granted to new employees hired to support the Company’s continued growth and an increase in the Company’s stock price at the grant dates during 2021.
Net Loss: The fourth quarter 2021 net loss was $36.9 million, or a net loss of $0.77 per share, and for the year ended December 31, 2021, net loss was $125.6 million, or a net loss of $2.71 per share, compared to the fourth quarter of 2020 net loss of $18.9 million, or a net loss of $0.48 per share, and for the year ended December 31, 2020, net loss of $66.2 million, or a net loss of $1.92 per share.